Therapeutic Product Immunogenicity Community

 View Only

  • 1.  Immunogenicity Discussion Group - MAR 5th | 12PM EST

    Community Leadership
    Posted 03-02-2025 22:24

    Join us this Wednesday at the AAPS Immunogenicity Discussion Group (IDG) on March 5th (12pm EST, 18-19h CET).

    We will host @Ching-Ha Lai (Vicky), @Michael Partridge, and other co-authors from Regeneron to present and discuss their recent AAPS Journal publication Challenging the Standard Immunogenicity Assessment Approach: 1‑Tiered ADA Testing Strategy in Clinical Trials' (https://doi.org/10.1208/s12248-024-00993-9).

    The article examines whether the same immunogenicity data interpretation can be obtained using 1-tiered and 3-tiered testing strategy, and whether the approach could be more widely applied to expedite data delivery and reduce resource needs in clinical development without compromising data quality or clinical interpretation.

    Submit your email address to receive a personal Teams meeting calendar invite.

    Todd & Rob



    ------------------------------
    Todd Lester
    BioAgilytix | Senior Director
    Durham, NC | [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------


  • 2.  RE: Immunogenicity Discussion Group - MAR 5th | 12PM EST

    Community Leadership
    Posted 03-06-2025 11:52

    Hi everyone,

    Thanks to the 100+ people who joined yesterday's AAPS Immunogenicity Discussion Group (IDG) discussion with Ching-Ha (Vicky) Lai, Sasha Fraser, Jessica Wang, Sean McAfee, Mu Chen and Michael Partridge from Regeneron presenting their recent AAPS Journal publication 'Challenging the Standard Immunogenicity Assessment Approach: 1‑Tiered ADA Testing Strategy in Clinical Trials' (https://doi.org/10.1208/s12248-024-00993-9).

    For those who were unable to join, the meeting recording is now available to view on demand at this link:

    https://youtu.be/nhfZllCHqec

    Many thanks!

    Rob & Todd



    ------------------------------
    Robert Nelson
    Scientific Officer, Senior Director
    BioAgilytix Europe GmbH
    Hamburg Germany
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer or other entities to which I am affiliated.
    ------------------------------

    Original Message